Uro Today Highlights
Read the full article here
Read the full article here
Conference
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), PARP inhibitors, BRCA2-mutant cancers, (ADP-ribose, Poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA2-mutant cancers, BRCA2-altered prostate cancers, SPOP Mutations.
prostate cancer, Novel Hormone Therapy, Coordination of Care in High-Risk Biochemically Recurrent Prostate Cancer, radical prostatectomy, apalutamide, darolutamide, enzalutamide, androgen deprivation therapy (ADT), EMBARK trial,…
Andrea Miyahira hosts Andrew Goldstein to discuss his group’s research on prostate cancer, published in Nature Cell Biology. Dr. Goldstein, along with his team, including…
Evan Yu and Oliver Sartor discuss the VISION trial’s exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies…
At the 2024 UCSF-UCLA PSMA Conference, Louise Emmett emphasizes the importance of SPECT imaging in assessing early and interim responses to Lutetium PSMA therapy in…
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an…
Prostate Cancer, Metformin, NKX3.1, NKX3.1 Loss to Suppress Prostate Cancer Progression, NKX3.1 expression, prostate cancer progression, precision intervention in prostate cancer.
Zach Klaassen and Daniel George discuss the highlights from ASCO GU 2024 including the BRCAAway trial, a study focusing on the combination of PARP inhibitors…